2025年10月27日,MapLight治疗公司在其IPO筹集了2.963亿美元,现在将Nasdaq作为MPLT进行交易。 MapLight Therapeutics raised $296.3 million in its IPO on Oct. 27, 2025, and now trades on Nasdaq as MPLT.

MapLight治疗公司于2025年10月27日完成了其IPO,通过销售1 917万股,每股1 700美元,包括承保人购买的额外股票,筹集了2.963亿美元。 MapLight Therapeutics, Inc. completed its IPO on October 27, 2025, raising $296.3 million by selling 19.17 million shares at $17.00 each, including additional shares purchased by underwriters. 该公司根据“MPLT”对纳斯达克进行贸易,正在开发ML-007C-MA,这是第二阶段精神分裂症和阿尔茨海默氏病精神病试验的口服疗法。 The company, which trades on Nasdaq under “MPLT,” is developing ML-007C-MA, an oral therapy in Phase 2 trials for schizophrenia and Alzheimer’s disease psychosis. 交易由摩根士丹利,杰弗里斯,利林克合伙人和斯蒂菲尔管理. The offering was managed by Morgan Stanley, Jefferies, Leerink Partners, and Stifel.